Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for LY294002 (compound)
Most Correlated Studies
- Oncogenic PI3K mutations in cancer cells following growth factor deprivation
- Breast epithelial cells that are organized and disorganized in cell culture
- Embryonic EBRTcH3 stem cells with or without MYC(T58A) overexpression treated with LY294002
- CD4+ T cells age and culture condition comparisons treated with rapamycin or LY 294002
- Colon cancer SW480 cells expressing BOP1, CSK2 or NFIL3 treated with different kinase inhibitors
Most Relevant Literature
- Effect of acupuncture preconditioning combined with PI3K blocker LY294002 on airway inflammation in …
- Synergistic effects of LY294002 and ABT199 on the cell cycle in K562, HL60 and KG1a cells.
- LY294002 attenuates inflammatory response in endotoxin-induced uveitis by downregulating JAK3 and in…
- Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in B…
- Autophagy inhibitors 3-MA and LY294002 repress osteoclastogenesis and titanium particle-stimulated o…
Most Relevant Clinical Trials
- SF1126 for Patients With Relapsed or Refractory Neuroblastoma
- Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer
- Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
- Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
- Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Meta…
